Cadrenal Therapeutics Statistics
Total Valuation
CVKD has a market cap or net worth of $6.88 million. The enterprise value is $332,391.
| Market Cap | 6.88M |
| Enterprise Value | 332,391 |
Important Dates
The next estimated earnings date is Monday, August 12, 2024.
| Earnings Date | Aug 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
CVKD has 16.01 million shares outstanding. The number of shares has increased by 48.61% in one year.
| Shares Outstanding | 16.01M |
| Shares Change (YoY) | +48.61% |
| Shares Change (QoQ) | -0.23% |
| Owned by Insiders (%) | 46.72% |
| Owned by Institutions (%) | 10.61% |
| Float | 7.18M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.11 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.21, with a Debt / Equity ratio of 0.00.
| Current Ratio | 8.21 |
| Quick Ratio | n/a |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -75.10% and return on invested capital (ROIC) is -83.58%.
| Return on Equity (ROE) | -75.10% |
| Return on Assets (ROA) | -68.20% |
| Return on Capital (ROIC) | -83.58% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.21M |
| Employee Count | 4 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -67.42% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -67.42% |
| 50-Day Moving Average | 0.46 |
| 200-Day Moving Average | 0.60 |
| Relative Strength Index (RSI) | 40.00 |
| Average Volume (20 Days) | 71,637 |
Short Selling Information
The latest short interest is 50,049, so 0.31% of the outstanding shares have been sold short.
| Short Interest | 50,049 |
| Short Previous Month | 42,155 |
| Short % of Shares Out | 0.31% |
| Short % of Float | 0.70% |
| Short Ratio (days to cover) | 0.54 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -5.19M |
| Pretax Income | -4.85M |
| Net Income | -4.85M |
| EBITDA | -4.84M |
| EBIT | -4.85M |
| Earnings Per Share (EPS) | -$0.31 |
Balance Sheet
The company has $6.57 million in cash and $15,167 in debt, giving a net cash position of $6.55 million or $0.41 per share.
| Cash & Cash Equivalents | 6.57M |
| Total Debt | 15,167 |
| Net Cash | 6.55M |
| Net Cash Per Share | $0.41 |
| Equity (Book Value) | 6.19M |
| Book Value Per Share | 0.39 |
| Working Capital | 6.17M |
Cash Flow
In the last 12 months, operating cash flow was -$3.95 million and capital expenditures -$1, giving a free cash flow of -$3.95 million.
| Operating Cash Flow | -3.95M |
| Capital Expenditures | -1 |
| Free Cash Flow | -3.95M |
| FCF Per Share | -$0.25 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CVKD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -48.61% |
| Shareholder Yield | -48.61% |
| Earnings Yield | -70.41% |
| FCF Yield | -57.44% |
Analyst Forecast
The average price target for CVKD is $3.50, which is 713.95% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $3.50 |
| Price Target Difference | 713.95% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -14.98% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |